March 11, 2025.
Announcement of individual stocks regarding the appointments of Company Executives.
Santen Pharmaceutical Co., Ltd. (headquartered in Osaka City) announces the following regarding the personnel affairs of Company Executives.
Record
Appointment of Company Executives effective April 1, 2025.
Name | New Position | Current Position |
---|---|---|
Takahiro Ito* | Representative Director, President, and CEO Representative Director, President, and CEO | |
Rie Nakajima* | Company Executives Company Executive Chief Operating Officer Company Executives Company Executive Chief Operating Officer | |
Itsuki Kurihara* | Company Executives Company Executive Director of Japan Business Administration and Global Commercial Strategy Company Executive Japan Business Administration and Global Commercial Strategy | |
Mariante Pusaha | Company Executive Executive Officer in charge of Europe, Middle East and Africa (EMEA) operations. In charge of Europe, Middle East and Africa (EMEA) operations. | |
Sean Chuan. | Company Executive Executive Officer in charge of China operations. In charge of China operations. | |
Shinichi Teramachi | Company Executive Japan Regional Ophthalmology Division Head and Sales General Manager Company Executive Japan Regional Ophthalmology Division Head and Sales General Manager | |
Tomoyuki Yoshida | Company Executive Asia Regional General Executive Asia Regional General | |
Seiko Watanabe | Company Executive Company Executives of the Pharmaceutical business in Japan Director of the Pharmaceutical business in Japan | |
Lear Hack*. | Company Executive Company Executives of the Ophthalmology Innovation Center Director of the Ophthalmology Innovation Center | |
Peter Salsitig*. | Company Executive Chief Medical Officer Company Executives Chief Medical Officer | |
Akaiho Bunpo* | Company Executive Chief of Staff (attached to CEO) Company Executives Chief of Staff (attached to CEO) | |
Kazuhiro Koshiji* | Company Executive Chief Financial Officer Company Executives Chief Financial Officer | |
Mika Masanari* | Company Executive General Counsel and Chief Compliance Officer Company Executives General Counsel and Chief Compliance Officer | |
Takahiro Morita | Company Executive Basic Philosophy & Sustainability Global Head Company Executive. Basic Philosophy & Sustainability Global Head. | |
Daisuke Nakata*. (Newly Appointed) | Company Executive Chief Digital & Information Officer Global Head of Digital & Information Technology. | |
Yoko Saiki* | Company Executive Corporate Strategy Global Head Company Executives. Corporate Strategy Global Head. |
* Corporate Management Member (CMM).
About Santen
Santen aims to contribute to the realization of people's 'Happiness with Vision' by providing valuable products and services to patients, consumers, and healthcare professionals worldwide in the ophthalmology field as a specialized company. Since its establishment, under the basic principle of 'Participating in Divine Work,' Santen has been pursuing the maintenance and enhancement of eye health for over 130 years. Currently, Santen globally conducts research and development, manufacturing, sales, and marketing activities of pharmaceuticals in the ophthalmology field, supporting the eye health of approximately 50 million people in over 60 countries and regions around the world. Our mission is to continue providing important value in the prevention, diagnosis, and treatment of eye diseases to patients and society through products and services created from ophthalmic expertise and patient perspectives that have not been provided before. To create a future where as many patients as possible can lead happy and fulfilling lives, we are committed to realizing a society where people around the world can experience happiness through 'seeing.'
For more details, please refer to our homepage.
– Contact information regarding this matter –
Santen Pharmaceutical Co., Ltd. Corporate Communication
Email: communication@santen.com
Comment(0)
Reason For Report